Skip to main content
. Author manuscript; available in PMC: 2009 Feb 1.
Published in final edited form as: Ann Behav Med. 2008 Feb 13;35(1):87–96. doi: 10.1007/s12160-007-9007-6

Table 2. Proliferative T-cell Responses to HPV-16 Synthetic Peptides by Group and HPV-status.

Patients (N = 74) Healthy Controls (N = 28)
Peptide All HPV16+ HPV16- All HPV16+ HPV16-
E624-45 41% (30/74) 14% (2/14)§ 47% (28/60)§ 46% (13/28) 67% (2/3) 44% (11/25)
E744-57 42% (31/74) 14% (2/14)§ 48% (29/60)§ 46% (13/28) 67% (2/3) 44% (11/25)
L1382-396 37% (27/74)* 7% (1/14)§ 43% (26/60)§ 61% (17/28)* 67% (2/3) 60% (15/25)

Note: The percentages reflect the number of subjects with SI≥ 3.0 (i.e. responders)/number of subjects tested.

*

indicates a significant difference between patients and control in proliferative response, p < 0.05.

§

indicates a significant difference between HPV16+ and HPV16- patients in proliferative response, p < 0.05.